Price (90d)
$9.76Signal Score (90d)
50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.13M | $-146.41M | $-0.49 |
| 2024 | $28.83M | $-162.86M | $-0.55 |
| 2023 | $38.02M | $-146.40M | $-0.51 |
| 2022 | $485.42M | $158.52M | $0.56 |
| 2021 | $375.20M | $153.46M | $0.56 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.18 per share
Typical surprise +26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.18 vs $-0.16miss
- Mon, May 11$-0.14 vs $-0.22beat
- Tue, Feb 24$-0.03 vs $-0.18beat
- Thu, Nov 6$-0.19 vs $-0.17miss
- Thu, Aug 7$-0.12 vs $-0.17beat
- Thu, May 8$-0.15 vs $-0.17beat
Estimates and results for ABCL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ABCLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (6)
- Newsbusinesswire.com·2d ago·Neutral
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
View source ↗ - Newsbenzinga.com·5d ago·Negative
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
View source ↗ - Newsmarketbeat.com·5d ago·Neutral
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
View source ↗ - Newsbusinesswire.com·7d ago·Neutral
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.
View source ↗